India’s first vaccine candidate against the novel coronavirus, COVAXIN, This has received a nod from the Drug Controller General of India (DCGI). Moreover, the officials approved it for further clinical trials Phase I and 2 in infected people.
Development Of The Vaccine
The vaccine is currently under development by Hyderbad-based biotechnology firm Bharat Biotech. Also, this project was in collaboration with the Indian Council of Medical Research and the National Institute of Virology. The clinical trials of the experimental COVID-19 vaccine in humans will begin in July 2020, Bharat Biotechsaid said in a note. And, this reports that the results are ‘promising’ and ‘show extensive safety and effective immune responses’.
Dr Krishna Ella, Chairman and MD of Bharat Biotech, said that the collaboration with ICMR and NIV proved instrumental in the development of this vaccine. Furthermore, the proactive support and guidance from CDSCO have enabled approvals to this project. And, they stated they worked tirelessly to deploy our proprietary technologies towards this platform.
The experts isolated SARS-CoV-2 strain in NIV, Pune and transferred to Bharat Biotech. Further, they developed and manufactured the indigenous inactivated vaccine in Bharat Biotech’s BSL-3 (Bio-Safety Level 3). Also, is a High Containment facility located in Genome Valley, Hyderabad the company stated recently The company hasn’t yet revealed details on how long the next steps are likely to take. It has also not revealed when the vaccine might be launched in the market or its rate.
In May 2020, Bharat Biotech got into a partnership with Thomas Jefferson University, Philadelphia, for an exclusive deal to develop a new vaccine candidate for COVID-19. And, they invented this invented at Jefferson. Additionally, the institution developed the vaccine using an existing deactivated rabies vaccine as a vehicle for coronavirus proteins.
Other Labs Reporting Development Of Covid Vaccines
Dr Matthias Schnell, an infectious diseases expert, along with his lab at Thomas Jefferson reportedly developed a vaccine in January. And. after this, they completed preliminary tests in animal models that showed a strong antibody response in mice receiving it.
Among the first companies in India to announce a vaccine candidate was Cadila Healthcare, located in Ahmedabad. Their candidate is currently in pre-clinical studies. Additionally, Pune biotech firm Serum Institute and Panacea Biotec in Delhi, are among others from India to develop a vaccine.